TRL1068
Phase 1Small molecule
TRL1068 is one of 36 small molecule programs targeting Chronic Rhinosinusitis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Chronic Rhinosinusitis
#DrugCompanyPhaseTrials
1Flovent
GSKPhase 3
Cinqair
TevaPhase 3
Tezspire
AstraZenecaPhase 3
Nurtec
PfizerPhase 3
Levaquin
WWim Janssens
Phase 3
PULMOZYME
RochePhase 3
Advil
KKenvue Brands
Phase 3
Oxycontin
PProtega
Phase 3
Fasenra
AstraZenecaPhase 2
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRL1068. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TTrellis Bioscience LLC